Topic: clinical trial data
BMJ authors are calling for more coordination between regulatory agencies in the Americas to improve health data transparency in clinical trials.
The efficacy and safety profile set the company up to compete with GW Pharmaceuticals in Dravet, sending Zogenix stock up 18% in premarket trading.
The data add to evidence that Antibe’s drug, ATB-346, is safer than naproxen, potentially making it a better choice for patients with osteoarthritis.
A top-line success against the pathological complete response rate endpoint in soft tissue sarcoma sent Nanobiotix’s stock up by more than 50%.
Setting the dose of the CXCR4 inhibitor tees X4 up to start the phase 3 portion of the rare immunodeficiency disease trial before the end of the year.
The study linked NY-ESO SPEAR T-cells to a 50% partial response rate in heavily pretreated cancer patients.
The trial linked the JAK1 inhibitor to significant improvements in symptoms, laying the groundwork for further development in psoriatic arthritis.
Early data suggest the new batch of therapies is at least as effective as its predecessor, clearing a potential pitfall on Spark’s path to market.
The positive readout further burnishes the prospects of the antibiotic, which is set to go before the FDA later this year.
A phase 2 trial of Allergy Therapeutics’ grass pollen candidate met its primary endpoint of showing a dose-response relationship.